CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News) today announced that new data from clinical and preclinical studies evaluating the company’s investigational small molecule cancer therapies – its mTOR inhibitor deforolimus, and its multi-targeted kinase inhibitor AP24534 – will be presented during the 20th Annual EORTC-NCI-AACR (ENA) Symposium on “Molecular Targets and Cancer Therapeutics,” being held in Geneva, Switzerland from October 21 through October 24, 2008.
